SCHEMBL7004889

SCHEMBL7004889

NCCCCCCCCCNC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 4/20 0.64
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 2/20 0.48
MEN1 O00255 1/20 0.48
PLG P00747 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
SLC6A2 P23975 1/20 0.48
RECQL P46063 1/20 0.48
SLC6A3 Q01959 1/20 0.48
KMT2A Q03164 1/20 0.48
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46
GNAI1 P63096 1/20 0.46
CYP2D6 P10635 1/20 0.44
NFKB1 P19838 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7010157 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL7007901 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL16247098 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL944344 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL1389554 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL3065839 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL7010487 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
Hydrochloric Acid SCHEMBL25353689 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15
Hydrochloric Acid SCHEMBL15155878 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15
Ammonia Solution, Strong SCHEMBL8683457 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208984-A1 BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS VIRGINIA COMMONWEALTH UNIVERSITY 2024-06-27 US disclosed
EP-4313051-A1 BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS Virginia Commonwealth University (US) 2024-02-07 EP disclosed
WO-2024010776-A1 AGENTS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-01-11 WO disclosed
WO-2023113456-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION (주)프레이저테라퓨틱스 2023-06-22 WO disclosed
WO-2020142228-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-07-09 WO disclosed
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 PAOX 2902/4885MAOA 1597/4885MAOB 2556/4885
US-20240208984-A1 BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS OPRM1, OPRK1, CCR5 PAOX 1885/4885MAOA 1042/4885MAOB 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.